Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib plus Irinotecan in Relapsed Small Cell Lung Cancer
NCT01941316Phase 2Completed
- Start
- Nov 2013
- Primary completion
- Dec 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of carfilzomib in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Primary endpoints: Maximum Tolerated Dose at 28 Days and Overall Survival Rate at 6 Months. Started Nov 2013; status: completed.
02
Drugs
carfilzomib
03
Conditions
small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01941316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941316.